Lipidor Announces Last Patient Out in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis
Lipidor AB (publ) today reports that the last patient has completed treatment in the phase III study evaluating the efficacy of using a sprayable calcipotriol product against mild to moderate psoriasis. Results from the study are expected to be presented in December 2019.Lipidor has developed a sprayable calcipotriol product, Calcipotriol/AKVANO 50 µg/g cutaneous solution (AKP01), formulated with the company’s lipid-based technology in order to provide more precise dosing, increased comfort, and non-touch treatment to patients. The phase III study is a comparative, randomized and placebo-